Story · Medicine & Biotech

Summit Therapeutics Secures $2 Billion AstraZeneca Investment as Ivonescimab Program Advances

1 outlet · first reported by OncoDaily 4d ago

Coverage, in order

  1. 4d ago
    OncoDaily obscure
    Summit Therapeutics Secures $2 Billion AstraZeneca Investment as Ivonescimab Program Advances

    Summit Therapeutics, Inc., shared on LinkedIn: “Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 Recent $2 Billion Strategic Equity

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.